Indication
Zepzelca, in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.
In other countries
The same active substances on other registers, the same brand first.
National listings
The national registers that list this EU medicine.
- Zepzelca 2 MG Polvo Para Concentrado Para Solucion Para PerfusionSpain · 2 mgAuthorised
- Zepzelca 4 MG Polvo Para Concentrado Para Solucion Para PerfusionSpain · 4 mgAuthorised
- ZEPZELCA 2 mg poeder voor concentraat voor oplossing voor infusieNetherlandsAuthorised
- ZEPZELCA 4 mg poeder voor concentraat voor oplossing voor infusieNetherlandsAuthorised